Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker CLNN · Nasdaq · DE
0/100
Clene Inc. is a U.S. business entity operating within the Pharmaceutical Preparations sector (SIC 2834). Publicly traded on the Nasdaq under the ticker symbol CLNN, the company is incorporated in Delaware. Based on SEC EDGAR filings, CLNN reported fiscal year 2022 revenue of $473K, reflecting a year-over-year decline of 34.6%. Our proprietary Semantic Risk Score of 14 indicates high transparency and low reporting risk, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 2834 classification, Clene Inc. serves as a key benchmark for investors and analysts monitoring Delaware corporate performance.
Estimated concentration for NAICS 325412 · Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparation Manufacturing
Industry mapping: Pharmaceutical Preparation Manufacturing
Filing data sourced from SEC EDGAR signals. 10-K = annual report · 10-Q = quarterly · 8-K = material event.
Numbers parsed from us-gaap XBRL tags in the company's most recent annual report.View source on SEC EDGAR →
Clene Inc. (CLNN) — Key efficiency & solvency metrics · FY2025
Debt-to-Equity
Sector avg: 1.36
Current Ratio
Sector avg: 4.84
| Key Metric | Company | Industry Avg | Status |
|---|---|---|---|
| Total Revenue | $473K | $1.89B | ▼ Lagging |
| Net IncomeYoY: +33.6% | $-26,173,000 | — | — |
| Debt-to-EquityTotal liabilities / stockholders equity. Lower = safer. | -2.03 | 1.36 | ▲ Stable |
| Current RatioCurrent assets / current liabilities. Above 1.0 = solvent. | 0.83 | 4.84 | ▼ Lagging |
Source: SEC EDGAR XBRL filings (10-K annual reports). Industry benchmarks derived from 311 companies in SIC 2834.
Disclaimer: All financial data is sourced from raw SEC EDGAR filings. Sprytne.com provides automated data visualization and algorithmic analysis for informational purposes only. This is NOT financial advice, a recommendation to buy/sell, or a guarantee of accuracy. Always verify data via official SEC sources before making investment decisions.
Federal Contracts
JANITORIAL SERVICE
JANITORIAL SERVICES FOR THE WESTERN REGIONAL CENTER, SEATTLE, WA
Contract details pending disclosure
JANITORIAL SERVICES, MARINE OPERATIONS CENTER - PACIFIC
JANITORIAL SERVICES (MONDAY, WEDNESDAY, FRIDAY)
JANITORAL - TACOMA VET CENTER
JANITORIAL SERVICES
JANITORIAL SERVICES
CLEAN 15,523 SQFT OF CARPET AT THE JAMES V. HANSEN FEDERAL BUILDING.
CARPET CLENEAR
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Import activity for Clene Inc. — based on US Customs & Border Protection (CBP) manifests.
| Date | Origin | Commodity | Weight | Shipper |
|---|---|---|---|---|
| 2025-11-02 | 🇩🇪 DE | Pharmaceutical excipients | 41.0 mt | DR. REDDYS LABORATORIES |
| 2025-09-22 | 🇻🇳 VN | Drug delivery capsule shells | 39.0 mt | CIPLA LTD |
| 2025-04-23 | 🇮🇳 IN | Pharmaceutical excipients | 34.1 mt | SUN PHARMA INDUSTRIES |
| 2025-03-27 | 🇹🇼 TW | Active pharmaceutical ingredients (API) | 16.5 mt | DR. REDDYS LABORATORIES |
| 2025-03-12 | 🇮🇱 IL | Drug delivery capsule shells | 2.6 mt | TEVA API |
| 2025-02-16 | 🇮🇳 IN | Vaccine cold-chain containers | 47.9 mt | TEVA API |
| 2025-01-27 | 🇮🇳 IN | Vaccine cold-chain containers | 46.0 mt | SUN PHARMA INDUSTRIES |
| 2025-01-02 | 🇮🇳 IN | Drug delivery capsule shells | 32.1 mt | SUN PHARMA INDUSTRIES |
| 2024-12-07 | 🇹🇼 TW | Active pharmaceutical ingredients (API) | 12.0 mt | DR. REDDYS LABORATORIES |
| 2024-11-15 | 🇨🇳 CN | Active pharmaceutical ingredients (API) | 13.9 mt | SUN PHARMA INDUSTRIES |
| Type | Person | Role | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
| ▼ SELL | Ugwumba Chidozie | 10% Owner | 72,884 | $6.80 | $496K | May 4, 2026 | SEC Filing |
| ▼ SELL | Ugwumba Chidozie | 10% Owner | 12,170 | $5.63 | $69K | Apr 29, 2026 | SEC Filing |
| ▼ SELL | Ugwumba Chidozie | 10% Owner | 61,345 | $6.14 | $377K | Apr 21, 2026 | SEC Filing |
| ▼ SELL | Ugwumba Chidozie | 10% Owner | 25,040 | $6.43 | $161K | Apr 17, 2026 | SEC Filing |
| ▼ SELL | Ugwumba Chidozie | 10% Owner | 24,925 | $4.81 | $120K | Apr 2, 2026 | SEC Filing |
Source: SEC EDGAR Form 4 filings. Only transactions >$50K shown.
Compared to 595 peers in Pharmaceutical Preparations (SIC 2834)
Revenue
Net Margin
SEC EDGAR XBRL filings by fiscal year
Side-by-side financial showdown — revenue, margins, and growth.
Based on NAICS.
America's #1 crypto exchange. Buy Bitcoin, Ethereum & 200+ coins.
Get Started Free →Affiliate link · sprytne.com may earn a commission
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of State public records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not affiliated with any government agency.Learn more →